Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer.

Animals Antimetabolites, Antineoplastic / administration & dosage Cell Line, Tumor Deoxycytidine / administration & dosage Drug Delivery Systems Humans Mice, Nude MicroRNAs / administration & dosage Nanostructures / administration & dosage Pancreatic Neoplasms / pathology Gemcitabine
Gemcitabine Nanoscale delivery Pancreatic cancer miR-345

Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
28 01 2019
Historique:
received: 22 06 2018
accepted: 17 12 2018
pubmed: 24 12 2018
medline: 21 3 2020
entrez: 22 12 2018
Statut: ppublish

Résumé

A polymeric dual delivery nanoscale device (DDND) was designed for combined delivery of microRNA (miR-345) and gemcitabine (GEM) to treat pancreatic cancer (PC). This temperature and pH-responsive pentablock copolymer system was able to restore miR-345, making xenograft tumors more susceptible to GEM, the standard therapy for PC. Restoration using DDND treatment results in sonic hedgehog signaling down regulation, which decreases desmoplasia, thereby resulting in improved GEM perfusion to the tumor and better therapeutic outcomes. The release of miR-345 and GEM could be tuned by using the DDND in the form of micelles or in the form of thermoreversible gels, based on polymer concentration. The DDNDs enabled miR-345 stability and sustained co-release of miR-345 and GEM, thereby facilitating dose-sparing use of GEM. Further, enhanced in vitro cellular uptake due to amphiphilic character, and endosomal escape because of the cationic end blocks led to efficient transfection with DDNDs. The combined DDND treatment enabled efficient reduction in cell viability of Capan-1 and CD18/HPAF cells in vitro compared with either GEM or miR-345 treatment alone. Mice carrying xenograft tumors treated with DDNDs carrying both miR-345 and GEM combination therapy displayed reduced tumor growth and less metastasis in distant organs compared to individual drug treatments. Immunohistochemical analysis of the xenograft tissues revealed significant down regulation of desmoplastic reaction, SHH, Gli-1, MUC4, and Ki67 compared to control groups.

Identifiants

DOI: 10.1016/j.jconrel.2018.12.031 PMID: 30576747 PMC: PMC6379902
pubmed: 30576747
pii: S0168-3659(18)30734-X
doi: 10.1016/j.jconrel.2018.12.031
pmc: PMC6379902
mid: NIHMS1517308
pii:
doi:

Substances chimiques

Antimetabolites, Antineoplastic 0
MIRN345 microRNA, human 0
MicroRNAs 0
Deoxycytidine 0W860991D6
Gemcitabine 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

237-246

Subventions

Organisme : NCI NIH HHS
ID : P50 CA127297
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183459
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM113166
Pays : United States

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Références

J Hematol Oncol. 2012 Oct 26;5:68
pubmed: 23102107
Oncogene. 2009 Oct 8;28(40):3513-25
pubmed: 19633682
Mol Ther Nucleic Acids. 2013 Apr 16;2:e84
pubmed: 23591808
Curr Pharm Des. 2011;17(21):2221-38
pubmed: 21777178
Cell. 2015 Mar 12;160(6):1099-110
pubmed: 25768906
Adv Drug Deliv Rev. 2015 Jan;81:128-41
pubmed: 24859533
Int J Pharm. 2012 May 1;427(1):88-96
pubmed: 22016031
Clin Cancer Res. 2008 Oct 1;14(19):5995-6004
pubmed: 18829478
J Control Release. 2018 Jun 10;279:1-7
pubmed: 29654797
Annu Rev Chem Biomol Eng. 2010;1:149-73
pubmed: 22432577
Int J Biol Sci. 2016 Jan 28;12(3):326-37
pubmed: 26929739
Oncotarget. 2016 Jan 26;7(4):4183-94
pubmed: 26716653
Adv Drug Deliv Rev. 2015 Jan;81:184-97
pubmed: 25281917
Mol Ther. 2013 May;21(5):986-94
pubmed: 23481326
ACS Nano. 2018 Mar 27;12(3):2426-2439
pubmed: 29533606
J Control Release. 2011 Aug 10;153(3):198-205
pubmed: 21663778
Acta Biomater. 2011 Apr;7(4):1580-7
pubmed: 21115139
Front Pharmacol. 2015 Dec 01;6:286
pubmed: 26648870
J Biomed Mater Res A. 2007 May;81(2):326-33
pubmed: 17120218
J Control Release. 2007 Aug 16;121(1-2):28-37
pubmed: 17614155
Eur J Pharm Sci. 2012 Mar 12;45(4):459-66
pubmed: 21925599
Int J Oncol. 2012 Dec;41(6):2093-102
pubmed: 23026911
Pharm Res. 2009 Mar;26(3):700-13
pubmed: 19142716
BMC Cancer. 2015 Jul 21;15:530
pubmed: 26189560
Biomaterials. 2008 Feb;29(5):607-17
pubmed: 17963830
Mol Pharm. 2014 Aug 4;11(8):2539-52
pubmed: 24742219
J Control Release. 2015 Jul 28;210:105-14
pubmed: 25979325
Br J Cancer. 2008 Jul 8;99(1):6-13
pubmed: 18577990
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
J Control Release. 2013 Dec 28;172(3):962-74
pubmed: 24075926
Genome Med. 2017 Jun 27;9(1):60
pubmed: 28655327
Eur J Cancer. 2013 Feb;49(3):593-603
pubmed: 22989511
World J Clin Oncol. 2016 Feb 10;7(1):27-43
pubmed: 26862489
Small. 2015 Sep 9;11(34):4321-33
pubmed: 26136261
Pancreas. 2004 Apr;28(3):219-30
pubmed: 15084961
J Control Release. 2013 Feb 28;166(1):1-9
pubmed: 23246471
Pharm Res. 2016 Jul;33(7):1587-601
pubmed: 26951567
Mol Pharm. 2015 Apr 6;12(4):1289-98
pubmed: 25679326
Transl Oncol. 2008 Mar;1(1):14-8
pubmed: 18607507
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Small. 2016 Sep;12(35):4837-4848
pubmed: 27432595
Langmuir. 2007 Jan 2;23(1):25-30
pubmed: 17190480
Int J Nanomedicine. 2014 Jun 18;9:2933-42
pubmed: 24971005
Acta Biomater. 2011 Apr;7(4):1570-9
pubmed: 21115141
Mol Ther Nucleic Acids. 2014 Sep 23;3:e194
pubmed: 25247240
Curr Drug Targets. 2013 Sep;14(10):1192-202
pubmed: 23834153
Pharm Res. 2011 Dec;28(12):2983-95
pubmed: 22009588
Br J Cancer. 2015 Aug 11;113(4):660-8
pubmed: 26247574
Biomaterials. 2014 Aug;35(25):7077-87
pubmed: 24836307
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
J Control Release. 2013 Nov 10;171(3):339-48
pubmed: 23665258
Curr Pharm Biotechnol. 2014;15(5):429
pubmed: 25189575
J Control Release. 2005 Mar 2;103(1):245-58
pubmed: 15710515
Mol Ther. 2004 Jul;10(1):19-26
pubmed: 15233938
Mol Pharm. 2013 Nov 4;10(11):4107-19
pubmed: 24066795
Mol Cancer Ther. 2011 Aug;10(8):1470-80
pubmed: 21622730
Mini Rev Med Chem. 2015;15(6):467-74
pubmed: 25807941
Int J Anal Chem. 2015;2015:862592
pubmed: 25838825
Biomaterials. 2016 Jan;76:144-56
pubmed: 26524535
ACS Nano. 2015 Mar 24;9(3):2290-302
pubmed: 25652012
Chin J Cancer. 2011 Aug;30(8):540-50
pubmed: 21801602
J Control Release. 2011 May 30;152(1):84-9
pubmed: 21295088
Biochim Biophys Acta. 2010 Jan;1805(1):97-104
pubmed: 19853645

Auteurs

Metin Uz (M)

Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA.

Manisha Kalaga (M)

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.

Ramesh Pothuraju (R)

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.

Juhyung Ju (J)

Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA.

Wade M Junker (WM)

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; Sanguine Diagnostics and Therapeutics, Omaha, NE, USA.

Surinder K Batra (SK)

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; Fred and Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; Eppley Institute for Research in Cancer & Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.

Surya Mallapragada (S)

Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA. Electronic address: suryakm@iastate.edu.

Satyanarayana Rachagani (S)

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: srachagani@unmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Actions chimiques et utilisations › Actions toxiques › Noxas › Antimétabolites › Antimétabolites antinéoplasiques › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Désoxycytidine › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris nude › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Dual delivery nanoscale device for miR-345 and...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Gemcitabine › Dual delivery nanoscale device for miR-345 and...